Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $45.4 million.

  • Ascendis Pharma A's Cash from Financing Activities fell 9033.36% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.5 million, marking a year-over-year decrease of 9283.24%. This contributed to the annual value of $480.5 million for FY2024, which is 23253.58% up from last year.
  • Ascendis Pharma A's Cash from Financing Activities amounted to $45.4 million in Q3 2025, which was down 9033.36% from $7.9 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash from Financing Activities ranged from a high of $469.9 million in Q3 2024 and a low of -$23.6 million during Q4 2021
  • Moreover, its 5-year median value for Cash from Financing Activities was $92967.8 (2024), whereas its average is $80.4 million.
  • In the last 5 years, Ascendis Pharma A's Cash from Financing Activities soared by 185025495.16% in 2022 and then plummeted by 57335.26% in 2023.
  • Ascendis Pharma A's Cash from Financing Activities (Quarter) stood at -$23.6 million in 2021, then skyrocketed by 105.83% to $1.4 million in 2022, then crashed by 573.35% to -$6.5 million in 2023, then skyrocketed by 101.43% to $92967.8 in 2024, then surged by 48758.28% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, $7.9 million for Q2 2025, and -$19.0 million during Q1 2025.